Pursuant to the terms of the agreement, FirstPoint Biotech (FPBT) will have the responsibility to undertake the clinical development and commercialization of these compounds within these fields of use and Ceragenix will provide ongoing consultation. The agreement covers the potential use of these compounds as both drugs and incorporation into medical devices such as condoms, sprays or gels. The agreement provides for payment of milestone payments and royalties.
Roslynne Flacks, executive chairman of FPBT said: “We believe that CSA-54 and other Ceragenin compounds may play a vital role in this effort and we plan to use the resources of a leading contract research organization with experience in HIV drug development to accelerate the development of these promising compounds.”